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Insulin-like growth factor-I (IGF-I) is an important 
regulator of epidermal proliferation and has been 
shown in vitro to be a powerful stimulator ofkeratino-
cyte growth. It is synthesized by fibroblasts in the 
dermis, along with several IGF-binding proteins 
(IGFBPs), which are known to modulate IGF-I respon-
siveness of virtually all tissues studied. Because it was 
not known how or in what form IGF-I produced in the 
dermis acts on epidermal keratinocytes in vivo, we in-
vestigated the possible role of IGFBPs in modulating 
the response of epidermal keratinocytes to IGF-1. We 
show here that tlGF-I, a non-IGFBP-binding ana-
logue ofIGF-1, is a more potent mitogenic stimulator 
of the keratinocyte cell line HaCaT than IGF-I, sug-
gesting that keratinocytes produce IGFBPs that modu-
I GF-I is a powerful mitogen for epidermal keratinocytes [1-5] . Although keratinocy. tes do not produce IGF-I themselves [5], they possess the IGF-I receptor [6] that confers thdr responsiveness to the hormone. There are two cell types that secrete IGF-I in the skin: fibroblasts in the underlying dermis 
and melanocytes in the epidermis [6]. The contribution of melano-
cytes to the pool of IGF-I in the skin may be only minor because 
they have a limited distribution, scattered thinly amongst th.e .kera-
tinocytes in the basal stratum of the epidermis [7 ,8]. Condlt1~ned 
medium from skin fibroblasts has been shown to stimulate keratmo-
cyte growth, and the effect can be blocked by antibodies to the 
IGF-I receptor, whereas a fibroblast cell line lacking IGF-I faded to 
support keratinocyte growth in a feeder layer syst~m [5]. It is th.ere-
fore likely that dermal fibroblasts can regulate epIdermal keratmo-
cyte growth in vivo via the IGF-I that they secrete; however, a role of 
IGF-I from melanocytes, or indeed from the circulation, cannot be 
discounted. 
In vivo, IGF-I occurs not as a free hormone, but as a complex with 
one of six IGF-binding proteins (IGFBP-1 to -6) , all which have 
been recently cloned and characterized [9,10]. In many cell types 
studied to date, IGF-I action at the cellular level appears to be mod-
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late their response to IGF-I. To confirm this and to 
identify which IGFBPs were produced, we analyzed 
HaCaT cell-conditioned medium and mRNA, with 
the following findings: HaCaT cells produce a major 
IGFBP, identified as IGFBP-3, and a minor 24-kD 
IGFBP, likely to be IGFBP-4. Northern analysis re-
vealed a 2.6-kb IGFBP-3 mRNA; however, IGFBP-4 
mRNA was not detectable. We conclude that produc-
tion of predominantly IGFBP-3 by the HaCaT cell line 
modulates its sensitivity to IGF-I stimulation. Epider-
mal IGFBPs thus have a potential role in vivo in the 
interaction of dermis derived IGF-I with epidermal 
keratinocytes. Key words: skin/epidermis/hormones. ] In-
vest Dermatoi103:627-631, 1994 
ulated by locally produced IGFBPs. III vitro, IGFBPs can either 
enhance . or inhibit IGF-I action, depending on the experimental 
procedure [11] . There have been only a few studies in whole animals 
?~ the in vivo actions of binding proteins, but in one study IGF-I 
111Jected as a complex WIth IGFBP-3 was more efficient at stimulat-
ing wound healing than IGF-I alone (12). 
In the present study, we hypothesized that IGFBPs are involved 
in the interacti~n of IGF-I with the keratinocytes of the basal layer 
of the epIdermis, the layer proximal to the source of IGF-I in the 
skin. To test this hypothesis, we analyzed the response of a basal 
keratinocyte cell-line, HaCaT, to IGF-I, and a non-IGFBP-
binding analogue, tIGF-I [13,14). We then investigated the pro-
duction of IGFBPs by this cell line. These keratinocytes do indeed 
pr?duce ~ specific sub-set ofIGFBPs, which appear to modulate the 
mltoge~lc action of IGF-I. This finding raises important questions 
co.ncerlllng the.role ofIGFBPs in the IGF-I response of the epider-
lUIS, and especIally m the basal stratum, in normal and aberrant 
epidermal proliferation. 
MATERIALS AND METHODS 
Materials Recombinant human insu lin-like growth factor-I (IGF-I) was a 
gift from Dr. A. Skottner (KabiPharmacia, Peptide Hormones, Sweden). 
Recombinant truncated huma.n IGF-I variant (t1GF-I , des 1-3 IGF-I) was 
kindly supplied by Dr. V.R. Sara (Karolinska Instimte, Stockholm, Sweden). 
[3-12SI-iodotyrosyl]IGF-I (2000 C i/mmol) , [methyl-3H]thymidine (6.70 
Ci/mmol) and molecular weight standards ([ 14C)-rainbow markers) wcre 
purchased from Amcrsham, Sydncy, Australia. The rabbit antisera R30. t, 
specific for human IGFBP-3, and A2, specific for human IGFBP-1 , were 
provided by Dr. R. Baxter, Sydney. aHEC-1, a rabbit antiserum specific for 
human IGFBP-2, was provided by Dr. R. Rosenfeld, Stanford University, 
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USA. The guinea-pig antiserum specific for human IGFBP-5 was provided 
by Dr. D. Clemmons, Chapel Hill, NC. The cDNAs for human IGFBP-2, 
-3, -4 and -5 [9] were provided by Dr. S. Shimasaki (Whittier Institute, La 
Jolla, CAl. T he human keratin 5 cDNA [15) was provided Dr. R. Leube, 
German Cancer Research Centre, Heidelberg. 
Cells The diffe rentiated human keratinocyte cell line, HaCaT [16), was 
kindly provided by Prof. N . Fusenig, German Cancer Research Centre, 
Heidelberg. Cel Is were used at passage numbers 33 to 36 and were passaged 
by washing 3-d post-confluent monolayers in phosphate-buffered saline 
(PBS), incubating in 3 mM ethylenediaminetetraacetic acid (EDT A) in PBS 
for 15 min then detaching the cells with 0.025 %(w Iv) trypsin, 0.02 %(w Iv) 
EDTA in PBS for 1- 2 min. Trypsin was inactivated by adding feta l bovine 
serum to 10%, which was then removed by washing the cells twice by 
centrifugation in keratinocyte serum-free medium (SFM) (Gibco). The cel ls 
were plated in keratinocyte-SFM (containing epidermal growth factor and 
bovine pituitary extract as supplied by the manufacturer) and maintained at 
37 ' C, 5% CO2 until use as described. Media containing fetal bovine serum 
were avoided because of the high content of IGF-I - binding proteins in 
serum. Before each experiment, cells were given several daily changes of 
keratinocyte-SFM, as described, to exclude totally the poss ibility of residual 
IGFBPs from serum. Cell counting was performed in a Coulter Industrial 0 
Counter, Coulter Bedfordshire, UK. 
Thymidine Incorporation Assay Cells were grown to 4 d post-con-
fluence in 2-cm2 wells with daily medium changes of keratinocyte-SFM; 
then the medium was changed to DMEM (Cytosystems, Australia), with the 
following additions: 25 mM Hepes, 0.19% (w Iv) sodium bicarbonate, 
0.03% (w/v) glutamine (Sigma Chemical Co., St. Louis, MO), 50 IU/ ml 
penicillin, and 50 Jig/ml streptomycin (Flow Laboratories). After 24 h, 
IGF-I or tIGF-I was added to triplicate wells, at the concentrations indicated, 
in 0.5 ml fresh DMEM containing 0.02% bovine serum albumin (Sigma 
molecular biology grade) and incubated for a further 21 h. [3H]-thymidine 
(0.1 JiCi/well) was then added and the cells incubated for a further 3 h. The 
medium was then aspirated and the ce lls washed once with icc-cold PBS and 
twice with ice-cold 10% trichloroacetic acid (TCA). The TCA-precipitated 
monolayers were then solubilized with 0.25 M NaOH (200 Jil/well) and 
transferred to scintillation vials, radioactivity was determined by liquid scin-
tillation countin g (Pharmacia W allac 1410 liquid scintillation counter). 
Western Ligand Blotting HaCaT-conditioned medium (250 Jil) was 
concentrated by adding 750 Jil cold ethanol , incubating at -20'C for 2 h 
and centrifugin g at 16,000 X g for 20 min at 4 'C. The resu lting pellet was 
air dried, resuspended thoroughly in non-reducing Laemmli sample buffer, 
heated to 90 ' C for 5 min, and separated on 12% sodium dodecylsulfate-
polyacrglamide gel electrophoresis according to the method of Laemmli 
l1 7). Separated proteins were electrophoretically transferred to nitrocel lu-
lose membrane (0.45 Jim, Schleicher and Schuell, Dassel, Germany) in a 
buffer containing 25 mM tris, 192 mM glycine. and 20% (v Iv) methanol. 
IGFBPs were then visualized by the procedure ofHossenlopp et al (18) , using 
[' 25I)-IGF-I, fo llowed by autoradiography. Autoradiographs were scanned 
in a BioRad Model GS-670 Imaging Densitometer and band densities were 
determined using the Molecular Analyst program. Data from Western lig-
and blots shown in Results represent identical data obtained in th ree separate 
experiments. 
lmmunoprecipitations HaCaT -conditioned medium (250 Jil) was pre-
absorbed with 80 Jil of a 25% suspension of protein A-Sepharose (Bio-Rad) 
in tris-buffered saline [25 mM tris-HCI, pH 7.4, 0.9% (w/v) NaCI] contain-
ing 0.1 % bovine serum albumin for 5 h at 4 'C with gentle rotation. After 
centrifugation at 16,000 X g for 5 min to remove protein A-Sepharose. 2Jil 
anti-IGFBP-3 antiserum,S Jil an ti-IGFBP-1 anti serum. 5 III anti - IGFBP-2 
antiserum,S Jil anti - IGFBP-5 antiserum. or 5 Jil pre-immune rabbit serum 
was added. together with 80 Jil fresh protein A - Sepharose suspension. Sam-
ples were incubated at 4· C with gentle rotation overnight. The samples 
were centrifuged and the protein A-Sepharose pellets were washed three 
times in tris-buffered saline, 0.1 % bovine serum albumin at 4 · C . Non-re-
ducing Laemmli sample buffer (50 Jil) was then added and the samples 
analyzed for IGFBPs by Western ligand blotting as described above. 
Northern Analysis HaCaT cells were grown to 4 d post-confluence in 
60-cm2 dishes with dai ly medium changes ofkeratinocyte-SFM. Total RNA 
was prepared by the method ofChomczynski and Sacchi [1 9). RNA (30 Jig) 
was denatured at 55 ' C for 1 h in 1 M glyoxal, 50% dimethylsulforide, 10 
mM NaPO •• pH 7.0, and electrophoresed in a 1 % agarose gel in 10 mM 
NaPO., pH 7.0. After transfer to Hybond-N (Amersham) in 20 X SSC (3 M 
NaCI, 0.3 M trisodium citrate dihydrate. pH 7.0), RNA was UV cross-
linked (2.5 J/cm2 ) and the membrane pre-hybridized for 4 h and probed 
overnight in a solution containing 2.5 X SSC (0.38 M NaCI, 0.038 M 
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Figure 1. Stimulation of thymidine uptake in HaCaT cells by IGF-I 
and tIGF-I. Post-confluent HaCaT cells were maintained as described in 
Materials a .. d Met/,ods, transferred to serum-free DMEM for 24 h. then incu-
bated for 24 h in IGF-I (e) or tlGF-I (.) at the concentrations indicated. 
Thymidine uptake was determined as in Materials a .. d Methods. The poi .. ts and 
error bars represent the mean of triplicate wells ± SD. 
trisodium citrate dihydrate. pH 7.0), 50% (v Iv) fo rmamide. 0.05% (w Iv) 
sodium pyrophosphate. 5 X Denhardt's solution, 25 mM sodium phos-
phate. 0.5% (w/v) sodium dodecylsulfate, and 100 Jig/ml of boiled herring 
sperm DNA at 48'C. The membrane was probed with eDNAs for human 
IGFBP-2, -3, -4, or -5, and labeled with 0'- [32P)-dCTP (Amersham, 3000 
Ci/mmol) by the random priming method (Boehringer Mannheim kit). 
The membrane was then washed 3 X 20 min in 2 X SSC/0.1 % sodium 
dodeeylsulfate at room temperature and autoradiographed. 
RESULTS 
Stimulation of HaC aT Cells by IGF-I and a Truncated Ana-
logue, tIGF-I IGF-I is a powerfu l mitogen for keratinocytes 
whereas tIGF-I is a truncated analogue of IGF-I that has little affin-
ity for the IGF-I - binding proteins, but which retains its affinity for 
the IGF-I receptor [13,14]. To determine whether the IGF-I re-
sponse of H aCaT cells is modulated by IGFBPs, we measured the 
relative potency of IGF-I versus tIGF-I in stimulating thymidine 
incorporation in HaCaT cells. Even though a direct comparison 
between cell number and thymidine incorporation rate as a measure 
of mitogenic stimulation has so far not been undertaken in the 
H aCaT cell line, the rate of thymidine incorporation has been 
shown to be a valid indicator of mitogenic stimulation in other 
cultured keratinocytes [20] . As shown in Fig 1, thymidine incorpo-
ration was significantly increased in response to IGF-I as expected. 
Interestingly. however, tIGF-I was 10 times more potent as a mito-
gen, implying that IGFBPs playa significant role in modulating the 
IGF-I stimulation of basa l keratinocytes, at least ill vitro. 
Investigation of IGFBPs in HaCaT Cell Conditioned Me-
dium by Western Ligand Blotting To determine which 
IGFBPs are responsible for modulating the IGF-I response of 
H aCaT cells, we analyzed HaCaT cell conditioned m edium as fol-
lows. HaCaT cells were grown to 1 d post-confluence in a 9-cm2 
dish . After a change of m edium, cells were incubated for a further 3 
d; then the H aCaT conditioned m edium was examined for the 
presence of IGFBPs by W estern ligand blotting as described in 
Materials and Methods. As shown in Fig 2A, the m ajor species is a 
doublet running in the 38 - 46-kD size range, identical in size to the 
human serum IGFBP-3 (Fig 2B) . The size o f this IGFBP is also 
consistent with that of IGFBP-3 produced by human skin fibro-
blasts as previously repor ted [21] and the cloned human IGFBP-3 
expressed in Chinese hamster ovary cells [22]. There is a minor 
24-kD species, consistent with human IGFBP-4 and appearing at 
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Figure 2. Secretion ofIGFBPs by HaCaT cells. One day post-confluent 
HaCaT cells were grown in a 9-cm2 dish for 3 d 11l keratmocyte-SFM and the 
IGFBPs in the resulting conditioned medium were measured by Western 
ligand blotting as described in Materials arid Methods. A, 250 Jll HaCaT 
conditioned medium; B, 5,u1 human serum; C, molecular weight standards. 
the same position as IGFBP-4 in human serum (Fig 2B) .. Scanning 
densitometry indicated that the major doublet contnbut~d to 
greater than 95% of the [1251]_ IGF-I binding to the Western hgand 
blot (data not shown). No other bands were visible ev.en after. ex-
tended autoradiography. No IGFBPs were detectable m keratmo-
cyte-SFM medium alone (data not shown). . . 
The kinetics of the appearance of the tw~ IGFBP speCle~ m the 
HaCaT cell conditioned medium was investigated by allowmg the 
HaCaT cells to grow from low density to post-conflue~ce, .measur-
ing the amount ofIGFBP produced per day. As show~ m ~lg 3, the 
rate of appearance of the putative IGFBP-3 in the medIUm 111creased 
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Figure 3. Production of the major 38-46-kD IGFBP is increased 
after cell confiuence. HaCaT cells were plated at a density of 10,000 cells 
per 2-cm2 well and grown with daily changes ofkeratinocyte~SFM. I<?FBPs 
secreted during each 24-h period were measured as descnbed m Materials and 
Methods. At the days shown, replicate wells were trypsinized and counted in a 
Coulter counter (mean of triplicates ± SD). Closed circles, number of cells; 
shaded bars, relative band intensity, 38-46-kD IGFBP. 
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Figure 4. Immunoprecipitation of major 38-46-kD IGFPB. Two 
hundred fifty microliters of HaCaT-conditioned medium was immunopre-
cipitated with antisera specific for IGFBP-I, -2, -3, or -5, or pre-immune 
rabbit serum, as described in Materials and Methods. The resulting immuno-
precipitates were analyzed by Western ligand blotting, as in Materials arid 
Methods. Lanes: rabbit serum,S Jll pre-immune rabbit serum; anti BP- I, 5 JlI 
A2 anti-IGFBP-l antiserum; anti BP-2, 5111 aHEC-I anti-IGFPB-2 anti-
serum; anti BP-3, 2 III R30.1 anti-IGFBP-3 antiserum; anti BP-S, 5 JlI 
anti-IGFBP-5 antiserum (Materials and Methods). 
sharply as the cells reached confluence on day 13, with the rate of 
appearance reaching a maximum on day 17, 4 d after confluence. 
This indicates that the increase in IGFBP-3 abundance was not 
simply due to an increase in cell number. The rate of appearance of 
the 24-kD species in the medium was largely independent of cell 
density, with a barely detectable 24-kD band appearing in each 24 h 
conditioned medium (data not shown). 
Identification of the Major IGFBP Secreted by HaCaT 
Cells A characteristic of human IGFBP-3 is its susceptibility to 
attack by a protease found in pregnant serum, which makes it unde-
tectable by Western ligand blotting [23] . We used this characteristic 
to help identify the major IGFBP produced by HaCaT cells. HaCaT 
cell conditioned medium (250 J.lI) was incubated overnight (14 h) at 
37°C with 2111 oflate-term pregnant human serum (39 weeks). The 
major IGFBP was highly susceptible to proteolysis by the pregnant 
serum with less than 5% of the 38 -46-kD doublet band remaining 
detectable by Western ligand blotting, suggesting that it is indeed 
IGFBP-3; incubation of the conditioned medium without pregnant 
serum resulted in no proteolysis (data not shown) . 
The IGFBP was further characterized by immunoprecipitation 
with R30.1, an antiserum specific for human IGFBP-3. As shown in 
Fig 4, R30.1 precipitates the 38 - 46-kD doublet, whereas antibod-
ies to IGFBP- l, -2, and -5 do not precipitate any protein detectable 
by Western ligand blotting. 
Analysis of IGFBP mRNA in HaCaT Cells To determine 
whether the IGFBPs detected in conditioned media reflect the 
IGFBP species being actively transcribed by HaCaT cells grown 
under these conditions, total RNA from confluent monolayers of 
HaCaT cells was subjected to Northern analysis, probing with 
cDNAs for IGFBP-2, -3, -4, and -5 . In addition, Northern blots 
were probed with a human keratin 5 cDNA to confirm that the 
HaCaT cells maintained their basal keratinocyte phenotype. As 
shown in Fig 5, an IGFBP-3 cDNA hybridizes to a single 2.6-kb 
mRNA species (Fig 5, BP-3, h), which is the same size as that of the 
human liver IGFBP-3 mRNA reported previously [22]. The appar-
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Figure 5. Identincation of IGFBP-3 mRNA in HaCaT cells. Total 
RNA (30 !lg) was prepared from post-confluent dishes of HaCaT cell s, 
denatured in glyoxal, electrophoresed in 1 % agarose, and transferred to 
Hybond-N membrane as described in Materials al1d Methods. Additionally, 
tota l RNA from pre-pubertal rat kidney, cultured human skin fibrob lasts, 
and cultured human epidermal keratinocytes was prepared and treated in the 
same manner to provide positive controls for hybridization of the eD NA 
probes in the case of IGFBP-2, -3, a~d -4 (rat kidney), or IGFBP-5 and 
keratin 5 (human fibroblasts and kerat1l1ocytes). The membranes were then 
probed with 32P-labeled cDNAs for IGFBP~2, -3, -.4, -5 and keratin 5, 
washed and autoradiographed, all as described 111 Materials aud MetllOds. POSI-
tions of 18S and 28S ribosomal RNAs, determined by ethidium bromide 
staining, are shown. rk, 30 !lg pre-pubertal rat kidney total RNA; h, 30 !lg 
HaCaT total RNA; hf, 30!lg cultured human skin fibroblast tota l RNA; s, 
30 !lg cultured human epidermal keratinocyte tota l RNA; BP-2, filter 
probed with 32P-labeled lGFBP-2 eDNA; BP-3, fi lter probed with 32P_la_ 
beled IGFBP-3 eDNA; BP-4, filter probed with 32P-labeled IGFBP-4 
eD NA; BP-S, filter probed with lOP-labeled IGFBP-S eDNA; KS, filter 
probed with 32P-labeled keratin S eDNA. The KS filter was autorad io-
graphed for S h, except for track h' (14 It). All other filters were autoradio-
graphed for between 3 and 21 d. 
ently low abundance of the IGFBP-3 mRNA contrasts with the 
easily detectable level of IGFBP-3 protein seen in W estern ligand 
blots. An IGFBP-4 mRNA could not be detected even after ex-
tended autoradiography (Fig 5, BP-4, h). The 1.9-kb band appear-
ing in this track and in the pre-pubertal rat kidney (Fig 5, BP-4, rk) 
is likely to be 18S ribosomal RNA because IGFBP-4 cDNAs have 
been shown to cross-hybridize strongly with 18S rRNA by others 
[24]. Figure 5 (BP-4, rk) also shows hybridization of the human 
IGFBP-4 eD NA to a single 2.4-kb IGFBP-4 mRNA in pre-pubertal 
rat kidney as expected. No mRNAs for IGFBP-2 (Fig 5, BP-2, h) or 
-5 (Fig 5, BP-5, h) were visible in HaCaT cells, which is consistent 
with the lack of any IGFBPs with molecular weights between 26 
and 34 kD detectable by Western ligand blotting. As evidence that 
HaCaT cells grown under these conditions maintain their basal 
keratinocyte phenotype, a 2.3-kD mRNA strongly hybridizing 
with the human keratin 5 eDNA was visible (Fig 5, K5, hand h') . 
The same band was visible in to tal RNA from cultured human 
foreskin keratinocytes (Fig 5, K5, s) and is consistent with the 
reported size of keratin 5 mRNA from human skin [25] . Control 
tracks show hybridization of IGFBP-2, -3, and -4 cDNAs with 
pre-pubertal rat kidney RNA (Fig 5, BP-2, -3, -4, rk), hybridization 
of the IGFBP-5 eDNA with human cultured skin fibroblast RNA 
(Fig 5, BP-5, hf) and a lack of hybridization of the human keratin 5 
eD NA with pre-pubertal rat kidney RNA (Fig 5, K5, rk). The use 
of pre-pubertal rat kidney as positive controls for hybridization of 
the human IGFBP-2, -3, and -4 cD NAs is warranted because of the 
extremely high inter-species conservation in these IGFBPs [9] . 
DISCUSSION 
The findin gs of this study, i) that a non -IGFBP-binding analogue 
of IGF-I (tIGF-I) is a more potent mitogenic stimulator of a basal 
keratinocyte cell line than IGF-I and ii) that HaCaT keratinocytes 
actively secrete IGFBPs in culture, together lead to the conclusion 
that basal keratinocytes modulate their own response to IGF-I via 
IGFBPs. We have shown that the predominant IGFBP produced by 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
these cells is IGFBP-3. An additional observation is that the rate of 
IGFBP-3 secretion significantly increases several days after con-
fluence is reached. Other keratinocyte proteins, namely, keratins 4, 
13, and 15, are similarly up-regulated at confluence in HaCaT cells 
[26]. Extrapolating from this observation to basal keratinocytes in 
lIillO, it is possible that these post-confluent, contact-inhibited mon-
olayers approximate the microenvironment in normal skin more 
closely than rapidly dividing, widely spaced cells. 
Because HaCaT cells produce keratin 5 in culture and keratins 1 
and 10 after transplantation onto nude mice [16] , they reflect the 
phenotype of basal keratinocytes i/1 II i llO [27]. The basal stratum is 
the likely target for growth factors derived from the dermis. It is the 
only layer of the epidermis that is actively proliferating [27] and it 
gives rise to all of the differentiated keratinocytes found in the 
outwardly progressing layers of the epidermis. It is of interest, then, 
that this is also the layer with by far the highest level of IGF-I 
receptors in normal epidermis [28]. Thus if dermis-derived IGF-I is 
accessible to the basal layer, it is potentially very important in the 
development of the whole epidermis . This is supported by recent 
experiments with transgenic mice lacking either the IGF receptor 
or its ligands, IGF-I and IGF-II, which exhibited a severe inhibition 
of cell progression from the basal to the spinous layer, resulting in 
thin, translucent skin [29] . There may well be other roles for IGF-I 
in epidermal development in addition to the stimulation of basal 
keratinocyte proliferation, because there is some evidence that IGF-
I promotes keratinocyte differentiation [30] and enhances keratino-
cyte migration [31] . 
The role of IGF-I in epidermal growth cannot be elucidated 
without considering the role of IGFBPs in IGF-I availability or 
targeting. IGFBPs in skin have been best characterized to date in the 
dermis, where they can modulate IGF-I binding and IGF-I response 
in dermal fibrobl asts [32 - 35). Dermal fibroblasts produce IGFBP-
3, -4, -5, and -6 and although the individual roles of these dermal 
IGFBPs are not known, it is likely that they are involved in the 
autocrine or paracrine role of IGF-I in the dermis, and possibly the 
targeting of dermal IGF-I to the epidermis. The latter has been 
hypothesized previously [4] but the results of the present study 
suggest that epidermal IGFBPs could also play a significant role in 
IGF-I paracrine action. 
Because HaCaT is a cell line, we cannot rule out the possibility 
that IGFBPs other than those detected in this study are important in 
keratinocyte growth it! lIillo. However, the significance of predomi-
nantly IGFBP-3 expression in basal keratinocytes remains. The 
findings arc consistent with data from our laboratory that IGFBP-3 
mRNA synthesis was clearly localized to keratinocytes of the basal 
stratum in in situ hybridization studies on normal adult skin sections 
(in preparation) . An immunohistochemical study has also demon-
strated that IGFBP-3 expression in feta l skin is concentrated in the 
basal stratum [36] . To date, other irz lIitro studies have been limited to 
a skin carcinoma cell line [37] that also secreted IGFBP-3 and -4. 
The ability of IGFBPs to affect IGF-I avai lability or targeting to 
basal keratinocytes has potential sigrlificance in diseases involving 
dysregulated epidermal proliferation or differentation. For exam-
ple, the basal layer in the hyperprol iferating epidermis of psoriasis is 
massively over-represented and, for this reason, so is the IGF-I re-
ceptor [28] . For a proper understanding of this and other diseases 
involving epidermal hyperproliferation, the effect of other epider-
mal growth regulators on IGFBP synthesis is likely to be an impor-
tant consideration. 
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